Table 1 Clinical studies on risk factors of ILD caused by lung cancer targeted therapy
No | Author, publication time | EGFR-TKIs | Number of study people | Onset time of ILD | Incidence/mortality of ILD | Incidence of ILD (≥ grade 3) | AIP/DAD | |
|---|---|---|---|---|---|---|---|---|
General population | Patients with concurrent or previous ILD | |||||||
1 [17] | Katsuyuki Hotta, (2005) | Gefitinib | 330 | Median time of onset was 22d | 15 (4.5%)/8 (53.3%) | 6 (30.0%)/5 (83.3%) | 12 (3.6%) | 6 (40.0%) |
2 [18] | Masahiko Ando, (2006) | Gefitinib | 1976 | median time of onset was 31d | 70 (3.5%)/31 (44.3%) | 5 (13.9%)/– | – | – |
3 [19] | Shoji Kudoh, (2008) | Gefitinib | 1901 | Onset within 28d was most common | 79 (4.2%)/25 (31.6%) | – | – | – |
4 [20] | Katsuyuki Hotta, (2010) | Erlotinib (group A) vs gefitinib (group B) | 539 | Median time of onset was 13d | Group A: 2 (1.0%) /0 (0%); Group B: 8 (2.4%) /6 (75%) | Group A: 1 (20.0%)/0 (0%); Group B: 5 (25.0%)/4 (80.0%) | Group A: 0 (0%); Group B: 8 (2.4%) | Group A: 0 (0%) Group B: 5 (62.5%) |
5 [21] | Shigeo Kawase, (2011) | Gefitinib or erlotinib | 341 | Median time of onset was 19d | 20(5.9%)/9(45.0%) | 9 (8.8%)/6 (66.7%) | – | 5(25%) |
6 [22] | Akihiko Gemma, (2014) | Erlotinib | 9909 | Median time of onset was 28d | 429 (4.3%)/153 (35.7%) | – | 257(2.6%) | 63(14.7%) |
7 [23] | Takeshi Johkoh, (2014) | Erlotinib | 627 | 80.0% occurred within 28 days | 19 (3.0%)/6 (31.6%) | 5 (10.6%)/0 (0%) | 9 (1.4%) | – |
8 [24] | Akihiko Gemma, (2018) | Crizotinib | 2028 | 41.9% occurred within 4 weeks; 69.2% occurred within 8 weeks | 117 (5.8%)/22 (18.8%) | 15 (23.1%)/– | 70 (3.5%) | 32 (27.4%) |
9 [25] | Akihiko Gemma, (2020) | Osimertinib | 3578 | Median time of onset was 63d | 231 (6.5%)/29 (12.6%) | 20 (19.23%)/– | 104 (2.9%) | 26 (11.3%) |
No | Author, publication time | Targeted drugs | Risk factors of ILD |
|---|---|---|---|
1 [17] | Katsuyuki Hotta, (2005) | Gefitinib | Previous pulmonary fibrosis; PS of 3–4 points; radiotherapy history |
2 [18] | Masahiko Ando, (2006) | Gefitinib | Concurrent ILD; male; smoking history |
3 [19] | Shoji Kudoh, (2008) | Gefitinib | Preexisting ILD; PS (> 2 points); older age (> 55 years old); smoking history; short duration since NSCLC diagnosis (< 6 months); reduced extent of normal lung on CT scan (< 50%); concurrent cardiac disease |
4 [20] | Katsuyuki Hotta, (2010) | Erlotinib (group A) vs gefitinib (group B) | Previous pulmonary fibrosis; PS of 3–4 points |
5 [21] | Shigeo Kawase, (2011) | Gefitinib or erlotinib | Previous pulmonary fibrosis |
6 [22] | Akihiko Gemma, (2014) | Erlotinib | Concurrent or previous ILD; emphysema or COPD; Lung infection; smoking history; time from cancer diagnosis to treatment (< 360 days) |
7 [23] | Takeshi Johkoh, (2014) | Erlotinib | Previous ILD; reduced extent of normal lung on CT scan (< 50%) |
8 [24] | Akihiko Gemma, (2018) | Crizotinib | Concurrent or previous ILD; older age; PS of 2–4 points; smoking history; concurrent pleural effusion |
9 [25] | Akihiko Gemma, (2020) | Osimertinib | Concurrent or previous ILD; history of using nivolumab |